Xomolix 2.5mg/1ml solution for injection ampoules

Land: Storbritannien

Sprog: engelsk

Kilde: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktiv bestanddel:

Droperidol

Tilgængelig fra:

Kyowa Kirin Ltd

ATC-kode:

N05AD08

INN (International Name):

Droperidol

Dosering:

2.5mg/1ml

Lægemiddelform:

Solution for injection

Indgivelsesvej:

Intravenous

Klasse:

No Controlled Drug Status

Recept type:

Valid as a prescribable product

Produkt oversigt:

BNF: 04020100; GTIN: 5038903000532

Indlægsseddel

PACKAGE LEAFLET: INFORMATION FOR THE USER
XOMOLIX 2.5 MG/ML SOLUTION FOR INJECTION
Droperidol
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or nurse.

If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Xomolix is and what it is used for
2.
What you need to know before you are given Xomolix
3.
How you will be given Xomolix
4.
Possible side effects
5.
How to store Xomolix
6.
Contents of the pack and other information
1.
WHAT XOMOLIX IS AND WHAT IT IS USED FOR
Xomolix is a solution for injection containing the active substance
droperidol, which belongs to a
group of antipsychotics called butyrophenone derivatives. Xomolix is
used to prevent you feeling sick
(nausea) or vomiting when you wake up after an operation or when you
receive morphine based
painkillers after an operation.
2.
WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN XOMOLIX
YOU SHOULD NOT BE GIVEN XOMOLIX IF YOU:

are allergic to droperidol, or any of the other ingredients of this
medicine (listed in section 6).

are allergic to a group of medicines used to treat psychiatric
disorders, called butyrophenones
(e.g. haloperidol, triperidol, benperidol, melperone, domperidone)

or anyone in your family have an abnormal electrocardiogram (ECG)
heart tracing

have low levels of potassium or magnesium in your blood

have a pulse rate of less than 55 beats per minute (the doctor or
nurse will check this), or are
taking any medicines that could cause this to happen

have a tumour in your adrenal gland (phaeochromocytoma)

are in a coma

have Parkinson’s disease

have severe depression
WARNINGS AND PRECAUTIONS
Talk to your doctor or nurse before using Xomolix:

if you have epilepsy, or a history of epilepsy

if you

Produktets egenskaber

OBJECT 1
XOMOLIX 2.5MG/ML SOLUTION FOR INJECTION
Summary of Product Characteristics Updated 30-Apr-2018 | Kyowa Kirin
Ltd
1. Name of the medicinal product
Xomolix
®
2.5 mg/ml solution for injection
2. Qualitative and quantitative composition
Each millilitre of the solution contains 2.5 mg droperidol.
Excipient with known effect: sodium < 23 mg per ml (see section 4.4
for further details).
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Solution for injection.
Clear colourless solution, free from visible particles.
The pH of droperidol solution for injection is 3.0 – 3.8 and has an
osmolarity of approximately 300
milliosmol /kg water.
4. Clinical particulars
4.1 Therapeutic indications
Xomolix is indicated in:
• Prevention and treatment of post-operative nausea and vomiting
(PONV) in adults and, as second line,
in children (2 to 11 years) and adolescents (12 to 18 years).
• Prevention of nausea and vomiting induced by morphine and
derivatives during post-operative patient
controlled analgesia (PCA) in adults.
Certain precautions are required when administering droperidol: see
sections 4.2, 4.3, and 4.4.
4.2 Posology and method of administration
Posology
Prevention and treatment of post-operative nausea and vomiting (PONV).
_Adults_: 0.625 mg to 1.25 mg (0.25 to 0.5 ml).
_Elderly (over 65 years): _0.625 mg (0.25 ml)
_Renal/hepatic impairment:_ 0.625 mg (0.25 ml)
_Paediatric population_
_Children (2 to 11 years) and adolescents (12 to 18 years): _10 to 50
microgram/kg (up to a maximum of
1.25 mg).
_Children (below the age of 2 years):_ not recommended.
Administration of droperidol is recommended 30 minutes before the
anticipated end of surgery. Repeat
doses may be given every 6 hours as required.
The dosage should be adapted to each individual case. The factors to
be considered here include age,
body weight, use of other medicinal products, type of anaesthesia and
surgical procedure.
Prevention of nausea and vomiting induced by morphine and derivatives
during post-operative patient
co